In contrast, certain cadherins, such as R‐cadherin (CDH4) and K‐cadherin (CDH6), can activate oncogenic pathways critical to cancer progression by regulating the activity of downstream effectors [5, 6]. This evidence concerns the gene CDH17 and cancer.